Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
    • Philanthropic Consulting
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Vaxart to Host Investor Q&A Webcast

BY GlobeNewswire
— 4:05 PM ET 06/16/2022

Management to discuss progress on its programs, annual stockholders’ meeting proposals

Webcast to be held on June 22 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) today announced that it will host a question-and-answer webcast with investors and analysts on Wednesday, June 22, 2022, at 1:00 p.m. Eastern Time. During the webcast, Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will provide an overview of the Company’s oral vaccine programs.

The Company will take written questions from investors and analysts. Please visit the webcast link to RSVP and submit written questions. Questions may also be submitted in advance to ir@vaxart.com.

A replay of the webcast will be available on the Investors page of the Company’s website at www.vaxart.com approximately two hours following the conclusion of the event.

As previously announced, Vaxart’s 2022 annual meeting of stockholders has been adjourned to Wednesday, July 6, 2022, at 12:30 p.m. Eastern Time. Vaxart (VXRT) encourages all stockholders of record on April 11, 2022, to vote their shares or change their votes in favor of all the proposals being submitted at the annual meeting by 11:59 p.m. Eastern Time on July 5, 2022.

About Vaxart (VXRT)
Vaxart (VXRT) is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart (VXRT) vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart (VXRT) believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart (VXRT) has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Note Regarding Forward-Looking Statements 
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's (VXRT) strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," "anticipate," "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's (VXRT) ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's (VXRT) expectations regarding clinical results and trial data; and Vaxart's (VXRT) expectations with respect to the effectiveness of its product candidates. Vaxart (VXRT) may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart (VXRT) makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's (VXRT) product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart's (VXRT) product candidates may not achieve broad market acceptance; that a Vaxart (VXRT) collaborator may not attain development and commercial milestones; that Vaxart (VXRT) or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's (VXRT) or its partners' control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart (VXRT) may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart's (VXRT) capital resources may be inadequate; Vaxart's (VXRT) ability to resolve pending legal matters; Vaxart's (VXRT) ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart (VXRT), if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the "Risk Factors" sections of Vaxart's (VXRT) Quarterly and Annual Reports filed with the SEC. Vaxart (VXRT) does not assume any obligation to update any forward-looking statements, except as required by law. 

Contacts

Vaxart Media Relations:Investor Relations:
Mark HerrAndrew Blazier
Vaxart, Inc. (VXRT)FINN Partners
mherr@vaxart.com
IR@vaxart.com
(203) 517-8957(646) 871-8486
Image: https://www.globenewswire.com/newsroom/ti?nf=ODU3MzkwNiM0OTg0MjQxIzIwMTkxMDk=
Image: https://ml.globenewswire.com/media/MDE0ZjU3OTMtNjM4Yi00YmY1LWE5YmUtNjdhZWE0MGZkNjEyLTEwMzA2ODI=/tiny/Vaxart-Inc-.png

Image: Primary Logo

Source: Vaxart, Inc. (VXRT)

More VXRT News

  • BRIEF-Vaxart Announces Adjournment Of Annual Meeting Of Stockholders
    Reuters - 9:12 AM ET 06/08/2022
  • Vaxart Announces Adjournment of Annual Meeting of Stockholders
    GlobeNewswire - 9:05 AM ET 06/08/2022
  • BRIEF-New Preclinical Data Demonstrate Two Of Vaxart'S Covid-19 Vaccine Candidates Protect Against Omicron
    Reuters - 8:06 AM ET 06/03/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close